SCHEMBL4376079

SCHEMBL4376079

COc1ccccc1CCC(=O)N1CCN(c2ccncc2)CC1

nearest known ligand 0.77

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.77
KMT2A Q03164 4/20 0.77
ALDH1A1 P00352 4/20 0.57
LMNA P02545 3/20 0.57
MAPT P10636 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.56
KDM4E B2RXH2 2/20 0.55
HTT P42858 2/20 0.54
CHRM1 P11229 1/20 0.53
SIGMAR1 Q99720 1/20 0.53
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MC4R P32245 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22813637 0.81 KMT2A (0.69) MEN1KMT2ALMNAKDM4ECHRM1
SCHEMBL4375414 0.81 TSHR (0.70) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL4377690 0.81 KMT2A (0.72) MEN1KMT2AALDH1A1L3MBTL1KDM4E
SCHEMBL4375437 0.81 KMT2A (0.72) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL8328048 0.80 KMT2A (0.68) MEN1KMT2AKDM4EHTTCHRM1
SCHEMBL8328272 0.80 KMT2A (0.67) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL14218028 0.79 KMT2A (0.76) MEN1KMT2AALDH1A1LMNAL3MBTL1
SCHEMBL4375389 0.79 FKBP1A (0.65) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL23244196 0.78 ME2 (0.67) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL29576134 0.78 ME2 (0.67) MEN1KMT2AALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 MEN1 2570/4885KMT2A 295/4885ALDH1A1 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.